Validating and Leveraging Non-SARS-CoV-2 Respiratory Infection as a Negative Control Outcome in a Phase 3 COVID-19 Vaccine Trial with Extended Observational Follow-Up
Published in American Journal of Epidemiology, 2025
Irrelevant infection endpoints confirmed as a valid negative control for COVID-19 and are leveraged to detect bias in hazard-based, time-varying vaccine efficacy estimates.
Recommended citation: Ashby, Ethan, et al. (2025). "Validating and Leveraging Non-SARS-CoV-2 Respiratory Infection as a Negative Control Outcome in a Phase 3 COVID-19 Vaccine Trial with Extended Observational Follow-Up." American Journal of Epidemiology. https://academic-oup-com.offcampus.lib.washington.edu/aje/advance-article/doi/10.1093/aje/kwaf176/8239036?utm_source=advanceaccess&utm_campaign=aje&utm_medium=email